AI-assisted MRI to improve MS care in the NHS
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis
We will try an AI tool that helps read brain MRI scans to find new MS lesions faster and more consistently for people with MS who are having routine MRI scans.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1336 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Queen Mary University of London Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT07111637 on ClinicalTrials.gov |
What this trial studies
People with clinically isolated syndrome (CIS) or confirmed multiple sclerosis who are on a disease-modifying therapy pathway and scheduled for a head MRI will have their scans processed with an AI-assisted software provided by icometrix. The AI output will highlight new or enlarging lesions and provide quantitative measures to support radiologists' interpretations and reports. The software is integrated into routine MRI workflows at Barts Health NHS Trust so that AI-supported reads can be compared with standard visual reads. Outcomes of interest include lesion detection rates, reporting time, and consistency of readings across scans and sites.
Who should consider this trial
Good fit: Ideal candidates are people with CIS or confirmed MS who are on an MS DMT pathway, are undergoing a head MRI, and have access to a smartphone, tablet, or computer.
Not a fit: Patients not undergoing MRI, not on an MS DMT pathway, or already enrolled in a randomized CTIMP may not be eligible or receive direct benefit from this intervention.
Why it matters
Potential benefit: If successful, the AI could help detect new lesions earlier, speed up MRI reporting, and reduce missed changes so treatment can be adjusted sooner.
How similar studies have performed: Previous research of AI-assisted MRI reading has shown promising results, with some reports of 3–4 times higher new-lesion detection compared with visual inspection alone.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically Isolated Syndrome suggestive of demyelination (CIS) or definitive diagnosis of MS. * Undergoing MRI head investigation. * On an MS DMT pathway. * Access to a smartphone, tablet or computer. Exclusion Criteria: * patients with Multiples Sclerosis participating in a randomised controlled CTIMP (participating in a single arm study may be included, provided this is in line with the other protocol).
Where this trial is running
London
- Barts Health NHS Trust — London, United Kingdom (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.